Taking stock of Alzheimer’s research, Biogen, and the amyloid hypothesis

Taking stock of Alzheimer’s research, Biogen, and the amyloid hypothesis

More reads

• Taking stock of Alzheimer’s research: Experts offer takes on Biogen, the NIH, and the amyloid hypothesis. (STAT Plus)
• Pfizer smashes expectations with tafamidis launch. (EP Vantage)
• Amgen third-quarter revenue falls 3%, biosimilar sales rise. (Reuters)
• The ‘cancer growing in cancer medicine’: pharma money paid to doctors. (STAT)